JP2009536153A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536153A5
JP2009536153A5 JP2009504433A JP2009504433A JP2009536153A5 JP 2009536153 A5 JP2009536153 A5 JP 2009536153A5 JP 2009504433 A JP2009504433 A JP 2009504433A JP 2009504433 A JP2009504433 A JP 2009504433A JP 2009536153 A5 JP2009536153 A5 JP 2009536153A5
Authority
JP
Japan
Prior art keywords
inhibitor
inhibitors
kinase
tyrosine kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009504433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/065908 external-priority patent/WO2007121088A2/en
Publication of JP2009536153A publication Critical patent/JP2009536153A/ja
Publication of JP2009536153A5 publication Critical patent/JP2009536153A5/ja
Pending legal-status Critical Current

Links

JP2009504433A 2006-04-05 2007-04-04 癌を処置するための治療剤の組合せ Pending JP2009536153A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78940206P 2006-04-05 2006-04-05
PCT/US2007/065908 WO2007121088A2 (en) 2006-04-05 2007-04-04 Combinations of therapeutic agents for treating cancer

Publications (2)

Publication Number Publication Date
JP2009536153A JP2009536153A (ja) 2009-10-08
JP2009536153A5 true JP2009536153A5 (enExample) 2010-05-20

Family

ID=38606595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504433A Pending JP2009536153A (ja) 2006-04-05 2007-04-04 癌を処置するための治療剤の組合せ

Country Status (11)

Country Link
US (2) US20100173934A1 (enExample)
EP (1) EP2004184A2 (enExample)
JP (1) JP2009536153A (enExample)
KR (1) KR20090005310A (enExample)
CN (1) CN101415420B (enExample)
AU (1) AU2007238307B2 (enExample)
BR (1) BRPI0709744A2 (enExample)
CA (1) CA2645278A1 (enExample)
MX (1) MX2008012717A (enExample)
RU (1) RU2449788C2 (enExample)
WO (1) WO2007121088A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
KR101309578B1 (ko) 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
KR101388776B1 (ko) 2012-07-31 2014-04-23 성균관대학교산학협력단 2，3―비스［（2―하이드록시에틸）티오］―1，4―나프토퀴논을 포함하는 항염증용 조성물
EP3131550B1 (en) * 2014-04-16 2021-05-26 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN106146509A (zh) * 2015-03-24 2016-11-23 重庆大学 一种抑制乳腺癌增殖的化合物及其应用
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2019071229A1 (en) * 2017-10-06 2019-04-11 Research Cancer Institute Of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR PREVENTING AND / OR TREATING NEOPLASMS
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
WO2003039536A1 (en) * 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
US6900331B2 (en) * 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
AU2003275068B2 (en) * 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B

Similar Documents

Publication Publication Date Title
JP2009536153A5 (enExample)
JP2009532503A5 (enExample)
Chung Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy
CN1113648C (zh) 四氢－β－咔啉衍生物作为抗转移瘤剂的用途
US20110112136A1 (en) Novel process for the manufacture of pharmaceutical preparations
HUP0203330A2 (hu) Benzamidszármazékot tartalmazó javított oldhatóságú és orális felszívódású gyógyszerkészítmények
GB2596884A (en) Pharmaceutical composition
HU230191B1 (hu) Nukleozidok mitokondriális betegségek kezelésére
JP2009531365A (ja) セラミドキナーゼ調節
FR2764511A1 (fr) Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
EA012701B1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
HUP0203160A2 (hu) Plakk ruptura kialakulásának megakadályozása ACAT-inhibitorok alkalmazásával
CA2153341A1 (fr) Application de la carbamazepine et de l'oxcarbazepine dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
JPH0219363A (ja) イミダゾリジン誘導体
JP2009532497A5 (enExample)
ES2601503T3 (es) Composición farmacéutica
UA82323C2 (uk) Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
JP2002520315A5 (enExample)
EP1093455A1 (en) Bis-indole derivatives and their use as antiinflammatory agents
KR20030078876A (ko) 편두통 재발의 예방
CN1306515A (zh) 蛋白质法尼基转移酶与HMG CoA还原酶抑制剂的组合及其治疗癌症的用途
US6713461B1 (en) Pharmaceutical complex
US5116600A (en) Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
EP0542979B1 (fr) Composition therapeutique pour liberation prolongee de magnesium
WO2005117864A1 (en) Combination product comprising anastrozole and a dual prenyl transferase inhibitor